肝细胞癌：临床医生的分子和基因组指南。

Hepatocellular carcinoma: molecular and genomic guideline for the clinician.

机构信息

The Methodist Center for Liver Disease, J.C. Walter Transplant Center, Department of Medicine, The Methodist Hospital, 6550 Fannin Street, SM 1001, Houston, TX 77098, USA.

出版信息

Clin Liver Dis. 2011 May;15(2):307-21, vii-x. doi: 10.1016/j.cld.2011.03.010.

DOI:10.1016/j.cld.2011.03.010

PMID:21689615

Abstract

Understanding of the genetic changes and molecular signaling pathways that are active in hepatocellular carcinoma has improved substantially over the last decade. As more information becomes available, it is clear that the prognostication of hepatocellular carcinoma will soon include molecular and genomic "fingerprints" that are unique to each cancer, which will allow more personalized treatment plans for patients as more targeted therapies become available. This article discusses the molecular and genomic changes that are important in hepatocellular carcinoma in order for clinicians to understand the current and forthcoming treatment options for patients with liver cancer.

摘要

在过去的十年中，人们对肝癌中活跃的遗传变化和分子信号通路有了更深入的了解。随着更多信息的出现，很明显，肝癌的预后很快将包括每个癌症特有的分子和基因组“指纹”，这将使更多针对特定靶点的治疗方法成为可能，从而为患者提供更个性化的治疗方案。本文讨论了肝癌中重要的分子和基因组变化，以便临床医生了解当前和即将出现的肝癌患者的治疗选择。